Although the results of some studies have substantiated the therapeutic anti-tumor efficacy of minimal epitope peptides, there is also evidence suggesting that synthetic long peptide vaccines may elicit more robust antigen-specific CD8+ T cell responses and potentiate greater tumor treatment effects compared to short peptide vaccines. The gene discussed is CD8A; the disease is neoplasm.